Transaction · 0001213900-26-114588

Davidson Matt

Davidson Matt, PRES, reported a transaction classified as grant at ADIAL PHARMACEUTICALS, INC. involving 1822.130000 shares. Reported holdings after the transaction were 1822.130000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code APRES
ADILADIAL PHARMACEUTICALS, INC.
Trade date
Oct 28, 2026
Filing date
Oct 31, 2026
View on SEC Insider profile
Disclosed valueUnknownShares × reported price
Shares traded1.82kPrice unknown
Holdings after1.82kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

ADIL price since this filing

Daily closing prices, with the filing date and available return windows
ADIL · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +8.9%1w ago +10.8%1d ago +0.0%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001213900-26-114588
Series A Preferred Stock
Transaction date
Oct 28, 2026
Filed Oct 31, 2026, 12:44 AM · 3d delay
Shares
1,822.13 sh
Price unknown
Estimated value
—
Computed from shares × price
Holdings after
1,822.13 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Increase
Filing-only score

-18 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
  • missing_price-8 points

    price_cents is null

    Missing price reduces confidence in value-based signals.
Missing facts
  • price_cents
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President and CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    On June 11, 2026, the Issuer acquired the private Delaware corporation which was then known as Azora Therapeutics, Inc. ("Old Azora") in accordance with the Agreement and Plan of Merger, dated June 11…

  2. F2

    Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Old Azora, with Old Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and im…

  3. F3

    As previously reported, represents an award of restricted stock units ("RSUs"). On June 11, 2026, the Issuer's board of directors approved the RSUs to be issued on June 12, 2026, contingent on stockho…

  4. F4

    Received, along with 61,647 shares of Common Stock previously reported, in exchange for 5,902,500 shares of Old Azora common stock in connection with the Merger Agreement.

  5. F5

    Subject to certain conditions set forth in the Merger Agreement (including receiving stockholder approval of the Preferred Stock Conversion Proposal) and the Certificate of Designation of the Series A…

  6. F6

    Received, along with 3,427 shares of Common Stock previously reported, in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 shares of Series A-2 Preferred Stock of Old Azora in con…

  7. F7

    The exercise price reported on this item corrects a scrivener's error on the Reporting Person's Form 4 filed on June 16, 2026, which inadvertently stated the exercise price for the option as $2.89. Th…

  8. F8

    As previously reported, on June 11, 2026, the Issuer's board of directors approved the option grant issued to the Reporting Person on June 12, 2026, contingent on stockholder approval of the Preferred…

  9. F9

    Received in exchange for a stock option to acquire 896,272 shares of Old Azora common stock with an exercise price of $0.17 per share, which grant was subject to stockholder approval of the Preferred…

  10. F10

    Immediately exercisable.

  11. F11

    Received in exchange for a stock option to acquire 100,000 shares of Old Azora common stock with an exercise price of $0.50 per share pursuant to the Merger Agreement, which grant was subject to stock…

  12. F12

    Received in exchange for a stock option to acquire 1,046,000 shares of Old Azora common stock with an exercise price of $0.20 per share pursuant to the Merger Agreement, which grant was subject to sto…

  13. F13

    The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust.

Original filing · 0001213900-26-114588
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ADIL